Content Type: Article

  • New OIG Guidance Signals Changed View of Compliance Programs

    ARTICLE

    New OIG Guidance Signals Changed View of Compliance Programs

    May 6, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Tony Maida wrote this bylined article on the new criteria used by the HHS Office of Inspector General (OIG) to evaluate healthcare provider corporate compliance programs. Compared to its approach 20 years ago, Mr. Maida wrote, OIG is now “starting from the premise that everyone in health care has a compliance program and if you do not you pose a higher risk” of non-compliance,” and added: “Now OIG is completing its pivot to its next goal — moving from encouraging the creation of compliance programs to operating effective compliance programs.”

    In depth
    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • Blocking a Bankruptcy Filing Still a Remote Possibility

    ARTICLE

    Blocking a Bankruptcy Filing Still a Remote Possibility

    May 6, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Darren Azman and Michael Galen wrote this bylined article on the recent decision In re Lake Michigan Beach Pottawattamie, calling it an example of the limits on a lender’s ability to create a bankruptcy-remote entity. “The decision in Pottawattamie serves as a reminder that when creating or modifying a blocking director’s obligations in a debtor’s organizational documents, a bankruptcy filing can never be absolutely prohibited,” the authors wrote.

    Read the full article (subscription required).

    In depth
    Authors

    Darren Azman

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • FB 2016: Hybrids – The Latest Changes

    ARTICLE

    FB 2016: Hybrids – The Latest Changes

    May 4, 2016

    Read time: 2 min

    Key takeaways
    Overview

    James Ross wrote this bylined article regarding a revised UK Finance Bill that greatly expands tax provisions covering hybrid mismatch arrangements which involve permanent establishments (PEs). “The effect of these changes is anticipated to be significant in terms of tax take,” Mr. Ross wrote, adding that the changes made “suggest that the government feels it has closed a significant loophole in the previous proposal.”

    In depth
    Authors
    More insights

  • Director and Officer Releases: Decision Underlines Importance of Detailed Language to Avoid Liability

    ARTICLE

    Director and Officer Releases: Decision Underlines Importance of Detailed Language to Avoid Liability

    May 3, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Darren Azman and Michael Galen wrote this bylined article on a recent Fifth Circuit case concerning reorganization plans which release claims against officers and directors that arose prior to or during the related bankruptcy case. Such releases are common and enforceable, the authors wrote, but the Fifth Circuit ruling “serves as a helpful reminder that poorly drafted releases may expose officers and directors to future litigation.”

    Read the full article.

    In depth
    Authors

    Darren Azman

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • Congress Passes the Defend Trade Secrets Act of 2016

    Congress Passes the Defend Trade Secrets Act of 2016

    ARTICLE / CLIENT ALERT

    Congress Passes the Defend Trade Secrets Act of 2016

    May 2, 2016

    Read time: 6 min

    Key takeaways
    Overview

    On April 27, 2016, the U.S. House of Representatives passed the Defend Trade Secrets Act of 2016, S. 1890 (the “DTSA”). The U.S. Senate had already passed the DTSA on April 4, 2016. The White House has expressed its support of the DTSA, and President Obama is expected to sign it into law within the next few weeks.

    The DTSA, among other things, provides owners of trade secrets with a federal private cause of action for the misappropriation of trade secrets. Currently, a patchwork of state laws, not federal law, allows individuals and entities to commence civil actions to protect their trade secrets and seek damages for misappropriation. Historically, federal law governing the protection of trade secrets has been limited to criminal statutes such as the Economic Espionage Act of 1996.

    In a previous Alert, we discussed an earlier version of this legislation (the Trade Secrets Protection Act of 2014, H.R. 5233) that was designed to provide trade secret owners with a federal private right of action to combat trade secret misappropriation. The legislation has since been modified in various ways and employers and other owners of trade secrets should become familiar with the key provisions.

    Key Provisions of the DTSA

    • Private Right of Action: The owner of a trade secret “related to a product or service used in, or intended for use in, interstate or foreign commerce” has the right to commence a civil action in federal court if such trade secret is misappropriated or if misappropriation is threatened.
    • Ex Parte Seizures: In “extraordinary circumstances,” a court may, upon ex parte application, “issue an order providing for the seizure of property necessary to prevent the propagation or dissemination of the trade secret that is the subject of the action.” Before issuing such a seizure order, an applicant must demonstrate to the court that the applicant otherwise would suffer irreparable and immediate injury, and that “the harm to the applicant of denying the application outweighs the harm to the legitimate interests of the person against whom seizure would be ordered of granting the application and substantially outweighs the harm to any third parties who may be harmed by such seizure.” The applicant also must demonstrate that the party subject to such an order “would evade, avoid, or otherwise not comply with” a preliminary injunction or temporary restraining order, and that, if the person subject to the order had prior notice of it, that person (or persons acting in concert with that person) “would destroy, move, hide, or otherwise make such matter inaccessible to the court.” An applicant for an ex parte seizure order must post an adequate security (as determined by the court). A court issuing an ex parte seizure order must hold a hearing no later than the seventh day following the issuance of such order to determine whether the order should be modified or dissolved.
    • Injunctions: A plaintiff may seek an injunction to prevent actual or threatened misappropriation. The DTSA places certain limitations on such injunctions. Most importantly, they may not “prevent a person from entering into an employment relationship.” Further, any conditions on employment cannot be based on a person’s mere knowledge of trade secrets (unlike employment conditions imposed under state law based on the inevitable disclosure doctrine). Rather, employment restrictions must be based on “evidence of threatened misappropriation.” The DTSA does not define what constitutes a “threatened misappropriation,” which may result in significant litigation. Injunctions under the DTSA may not conflict with applicable state law prohibitions on “restraints on the practice of a lawful profession, trade, or business.” These limitations were added to the DTSA after certain senators expressed concern that it would interfere with state laws designed to protect employee mobility. These limitations do not, however, limit the injunctions currently available under state law.
    • Damages: A plaintiff may seek damages for actual loss, plus any unjust enrichment in excess of actual loss, caused by the misappropriation of a trade secret. Alternatively, the plaintiff may collect a reasonable royalty for an unauthorized disclosure or use of a trade secret. A plaintiff also may collect exemplary damages up to twice the amount of damages otherwise awarded in the event of willful and malicious misappropriation of the trade secret.
    • Statute of Limitations: A civil action must be commenced within three years following the date on which the misappropriation was discovered or should have been discovered with reasonable diligence.
    • Preemption: The private cause of action set forth in the DTSA does notpreempt or displace state law governing the protection of trade secrets.
    • Immunity: The DTSA provides immunity from civil and criminal liability under federal or state trade secret law for individuals who disclose trade secrets in confidence to federal, state or local government officials, or to attorneys, in each case “solely for the purpose of reporting or investigating a suspected violation of law,” or in court filings made under seal. In certain circumstances, an individual who sues his or her employer for whistleblower retaliation may disclose that employer’s trade secrets to an attorney. Under the DTSA, employers must notify their employees, in any employment contract or agreement governing the use of trade secrets or confidential information that is entered into or modified after the DTSA is enacted, of their immunity in such circumstances.

    Considerations for Employers

    The DTSA provides employers with greater resources to protect trade secrets. Because the private cause of action under the DTSA will not preempt state law, employers will be able to pursue claims under both federal and state law. They also will have access to federal courts to pursue those claims. At the same time, the DTSA imposes additional burdens on employers. Employers will need to make sure that their employment contracts contain the proper notifications as required by the DTSA.

    Authored by Ronald E. Richman, Holly H. Weiss, Taleah E. Jennings and Frank P. Sabatini.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This information has been prepared by Schulte Roth & Zabel LLP (“SRZ”) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.

    In depth
    Authors

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Holly H. Weiss

    Retired Partner

    New York – 919 Third Avenue

    Taleah E. Baez

    Senior Partner

    New York – 919 Third Avenue

    More insights

  • The Chilling Ransomware Threat Facing Hospitals

    ARTICLE

    The Chilling Ransomware Threat Facing Hospitals

    April 2016

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Senate Finance Committee Considering Telehealth Options to Improve Care and Lower Costs

    ARTICLE

    Senate Finance Committee Considering Telehealth Options to Improve Care and Lower Costs

    April 2016

    Read time: 2 min

    Key takeaways
    Overview

    Lisa Schmitz Mazur, Dale Van Demark and Marshall Jackson wrote this bylined article on a Senate Finance Committee Policy Document which contemplates expanding the use of telehealth strategies to address the needs of Medicare beneficiaries with chronic conditions. “It is safe to assume that telehealth will continue to be integrated into new payment and care delivery models in support of the shift from fee-for-service to fee-for-value,” the authors wrote.

    In depth
    Authors

    Lisa Mazur

    Partner

    Chicago

    Marshall E. Jackson , Jr.

    Partner

    Washington, DC

    More insights

  • Biosimilar Product Labeling Guidance from FDA

    ARTICLE

    Biosimilar Product Labeling Guidance from FDA

    April 2016

    Read time: 2 min

    Key takeaways
    Overview

    Kristin Connarn wrote this bylined article on FDA suggested guidance for labeling biosimilar products. The FDA recommends that in biosimilar product labeling, applicants incorporate relevant data and information from the reference product label, with appropriate product-specific modifications, Ms. Connarn wrote, adding that “it is not required that the text be identical to that of the reference product label.”

    Read the full article.

    In depth
    Authors
    More insights

  • “Deemed to be a License” Guidance from FDA

    ARTICLE

    “Deemed to be a License” Guidance from FDA

    April 30, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Kristin Connarn wrote this bylined article on draft FDA guidance covering how certain products that the FDA has historically regulated as drugs will transition into biologics in March 2020. Ms. Connarn wrote that the draft guidance provides important information on preparing for the 2020 transition, including what happens to approved and pending applications for transitional products and how the transition will affect exclusivity.

    Read the full article.

    In depth
    Authors
    More insights

  • “Deemed to be a License” Guidance from FDA

    ARTICLE

    “Deemed to be a License” Guidance from FDA

    April 30, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Kristin Connarn wrote this bylined article on draft FDA guidance covering how certain products that the FDA has historically regulated as drugs will transition into biologics in March 2020. Ms. Connarn wrote that the draft guidance provides important information on preparing for the 2020 transition, including what happens to approved and pending applications for transitional products and how the transition will affect exclusivity.

    In depth
    Authors
    More insights